The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 29 | — | 20.1x | Below average | |
Growth | 9 | — | 5.6% | Below average | |
Quality | 36 | 944.6% | 7.6% | Near average | |
Safety | 29 | 0.6x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Seres Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Seres Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Current data for Seres Therapeutics indicates a state of extreme pessimism and shrinking analyst coverage. The target price has stabilized at 1.25 dollars, representing a sharp negative gap compared to the current trading price (7.92 dollars), reflecting analysts' lack of conviction in the current market valuation. It is noted that only one analyst is currently covering the stock, which raises the level of uncertainty and reduces the reliability of the arithmetic mean of the forecasts.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.